Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31619095 | 0.85 | TSHR (0.36) | AADATMAPTTSHR | |
| SCHEMBL31229253 | 0.77 | MAPT (0.38) | MAPTTSHRKDM4E | |
| SCHEMBL2666807 | 0.77 | MAPT (0.35) | MAPTTSHRKDM4E | |
| SCHEMBL20489480 | 0.74 | AADAT (0.42) | AADATMAPTTSHRKDM4EALDH1A1 | |
| SCHEMBL20489475 | 0.73 | PIK3CD (0.42) | AADATMAPTTSHRKDM4EMAPK1 | |
| SCHEMBL20489690 | 0.73 | ALDH1A1 (0.39) | AADATKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL31229328 | 0.73 | PIK3CD (0.42) | AADATMAPTTSHRKDM4EMAPK1 | |
| SCHEMBL20489660 | 0.72 | AADAT (0.44) | AADATMAPTHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL31229332 | 0.72 | MAPT (0.34) | MAPTTSHRALDH1A1 | |
| SCHEMBL31229249 | 0.65 | TSHR (0.45) | MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372601-B1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2022-09-21 | — | — | EP | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3372601-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | KAT2A, KAT7, KAT5 | AADAT 1539/4885MAPT 2348/4885TSHR 4130/4885 |
| US-10793582-B2 | Bicyclic heterocyclic compound | KAT2A, KAT7, KAT5 | AADAT 1329/4885MAPT 2057/4885TSHR 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.